Seleccione un Tamaño
About This Item
Fórmula empírica (notación de Hill):
C20H17F3N2O4
Número CAS:
Peso molecular:
406.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Nombre del producto
Tasquinimod, ≥98% (HPLC)
SMILES string
FC(F)(F)c1ccc(cc1)N(C)C(=O)c2[c]([n](c3c(c2O)c(ccc3)OC)C)=O
InChI
1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
InChI key
ONDYALNGTUAJDX-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Biochem/physiol Actions
Tasquinimod is an antineoplastic agent with immunomodulatory, anti-angiogenic and anti-metastatic activity. It showed good results in overall survival improvement in castrate resistant prostate cancer. Its mechanism of action is not known, but may involve Protein S100-A9 also known as migration inhibitory factor-related protein 14 (MRP-14).
immunomodulator that inhibits tumor angiogenesis; antineoplastic
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Andrew J Armstrong et al.
JAMA oncology, 4(7), 944-951 (2018-05-26)
Prostate cancer commonly metastasizes to bone, and bone metastases are associated with pathologic fractures, pain, and reduced survival. Bone disease is routinely visualized using the technetium Tc 99m (99mTc) bone scan; however, the standard interpretation of bone scan data relies
K Fizazi et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 28(11), 2741-2746 (2017-10-24)
This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy. Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25-1.0 mg/day orally) or
Yongquan Wang et al.
Journal of cancer research and clinical oncology, 144(9), 1751-1768 (2018-05-26)
Castration-resistant prostate cancer (CRPC) refers to prostate cancer that has progressed after initial androgen deprivation therapy (ADT). Over the years, treatment strategies for metastatic CRPC (mCRPC) have undergone considerable changes. We performed a network meta-analysis to assess the effectiveness and
Zhenchuan Liu et al.
Clinical and translational medicine, 11(9), e545-e545 (2021-09-30)
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive and treatment-resistant tumor. The biological implications and molecular mechanism of cancer stem-like cells (CSCs) in ESCC, which contribute to therapeutic resistance such as radioresistance, remain elusive. Quantitative real-time polymerase chain reaction
Mehdi Bouhaddou et al.
Cell, 182(3), 685-712 (2020-07-10)
The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies. Here we present a
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico